121 related articles for article (PubMed ID: 21072049)
1. The first case of acute lymphoblastic leukemia with the e19a2 BCR-ABL1 transcript: imatinib therapy followed by unrelated donor transplantation induces a durable molecular response.
Jeon EK; Lim J; Kim M; Yahng SA; Lee SE; Cho BS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Lee S
Leukemia; 2011 Feb; 25(2):366-7. PubMed ID: 21072049
[No Abstract] [Full Text] [Related]
2. Imatinib for relapsed BCR/ABL positive leukemias.
Ottmann OG; Wassmann B; Hoelzer D
Ann Hematol; 2002; 81 Suppl 2():S36-7. PubMed ID: 12611069
[No Abstract] [Full Text] [Related]
3. Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.
Millot F; Cividin M; Brizard F; Chomel JC; Méchinaud F; Guilhot F
Pediatr Blood Cancer; 2009 Jul; 52(7):891-2. PubMed ID: 19202569
[TBL] [Abstract][Full Text] [Related]
4. Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.
Wernstedt P; Brune M; Andersson PO; Gustavsson B; Stockelberg D; Wadenvik H
Bone Marrow Transplant; 2002 Dec; 30(12):971-3. PubMed ID: 12476293
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia.
Leoni V; Biondi A
Haematologica; 2015 Mar; 100(3):295-9. PubMed ID: 25740105
[No Abstract] [Full Text] [Related]
6. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.
Pfeifer H; Lange T; Wystub S; Wassmann B; Maier J; Binckebanck A; Giagounidis A; Stelljes M; Schmalzing M; Dührsen U; Wunderle L; Serve H; Brück P; Schmidt A; Hoelzer D; Ottmann OG
Leukemia; 2012 Jul; 26(7):1475-81. PubMed ID: 22230800
[TBL] [Abstract][Full Text] [Related]
7. Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation.
Oshikawa G; Kurosu T; Arai A; Murakami N; Miura O
Cancer Genet Cytogenet; 2010 May; 199(1):56-61. PubMed ID: 20417871
[TBL] [Abstract][Full Text] [Related]
8. Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia.
Piccaluga PP; Malagola M; Rondoni M; Amabile M; Paolini S; Soverini S; Gaitani S; Visani G; Baccarani M; Martinelli G
Eur J Haematol; 2004 Apr; 72(4):302-3. PubMed ID: 15089772
[No Abstract] [Full Text] [Related]
9. Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
Kim YJ; Kim DW; Lee S; Min CK; Goh HG; Kim SH; Lee JY; Kim YL; Kim HJ; Kim HJ; Lee JW; Kim TG; Min WS; Kim CC
Biol Blood Marrow Transplant; 2004 Oct; 10(10):718-25. PubMed ID: 15389438
[TBL] [Abstract][Full Text] [Related]
10. Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia.
Grammatico S; Elia L; Peluso AL; Pedace L; Matarazzo M; Vitale A; Rago A; Pane F; Foà R; Cimino G
Leuk Res; 2009 Jul; 33(7):e73-4. PubMed ID: 19108887
[No Abstract] [Full Text] [Related]
11. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of dasatinib in conjunction with alpha-interferon for the treatment of imatinib-resistant and dasatinib-resistant Ph+ acute lymphoblastic leukemia.
Visani G; Piccaluga P; Malagola M; Isidori A
Leukemia; 2009 Sep; 23(9):1687-8. PubMed ID: 19421228
[No Abstract] [Full Text] [Related]
13. Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment.
Scheuring UJ; Pfeifer H; Wassmann B; Brück P; Gehrke B; Petershofen EK; Gschaidmeier H; Hoelzer D; Ottmann OG
Leukemia; 2003 Sep; 17(9):1700-6. PubMed ID: 12970767
[TBL] [Abstract][Full Text] [Related]
14. [Clinical characteristics and outcomes of 59 patients with acute lymphoblastic leukemia positive for BCR/ABL].
Liu Z; Liu XL; Du QF; Xu N; Zhong M; Song LL; Yi ZS; Liu QF; Meng FY; Zhou SY
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Mar; 29(3):512-5. PubMed ID: 19304540
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias.
Shimoni A; Kröger N; Zander AR; Rowe JM; Hardan I; Avigdor A; Yeshurun M; Ben-Bassat I; Nagler A
Leukemia; 2003 Feb; 17(2):290-7. PubMed ID: 12592325
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment with imatinib-combined chemotherapy for relapsed Philadelphia-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation.
IMAHASHI N; TOKUNAGA M; NISHIWAKI S; YANAGISAWA M; OZAWA Y; MIYAMURA K
Rinsho Ketsueki; 2009 Nov; 50(11):1612-5. PubMed ID: 20009435
[TBL] [Abstract][Full Text] [Related]
17. Administration of imatinib in the first 90 days after allogeneic hematopoietic cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Chen H; Liu KY; Xu LP; Liu DH; Chen YH; Shi HX; Han W; Zhan XH; Wang Y; Zhao T; Huang XJ
Chin Med J (Engl); 2011 Jan; 124(2):246-52. PubMed ID: 21362375
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Caocci G; Vacca A; Ledda A; Murgia F; Piras E; Greco M; Arras M; Atzeni S; Littera R; La Nasa G
Biol Blood Marrow Transplant; 2012 Apr; 18(4):652-4. PubMed ID: 22240733
[No Abstract] [Full Text] [Related]
19. Long-term molecular remission with persistence of BCR-ABL1-specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphia-positive ALL.
Riva G; Luppi M; Lagreca I; Barozzi P; Quadrelli C; Vallerini D; Zanetti E; Basso S; Forghieri F; Morselli M; Maccaferri M; Paolini A; Fantuzzi V; Messerotti A; Maffei R; Iacobucci I; Martinelli G; Marasca R; Narni F; Comoli P; Potenza L
Br J Haematol; 2014 Jan; 164(2):299-302. PubMed ID: 24134676
[No Abstract] [Full Text] [Related]
20. Imatinib interim therapy between chemotherapeutic cycles and in vivo purging prior to autologous stem cell transplantation, followed by maintenance therapy is a feasible treatment strategy in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shin HJ; Chung JS; Cho GJ
Bone Marrow Transplant; 2005 Nov; 36(10):917-8. PubMed ID: 16113662
[No Abstract] [Full Text] [Related]
[Next] [New Search]
